Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort Scientific Corporation Announce Leadership Changes in MicroPort Orthopedics Subsidiary and Membership Changes in CEC, IEC


MicroPort Scientific Corporation announce leadership changes in MicroPort Orthopedics subsidiary
China, Shanghai - MicroPort Scientific Corporation ("MPSC") is pleased to announce, after approval by the Board of Directors, effective September 8th, 2015 the appointment of Mr. Aurelio Sahagun as President of MicroPort Orthopedics. Mr. Ted Davis, will depart the role of Chief Executive Officer on the same date, and has committed to working closely with Aurelio to ensure a smooth and seamless transition. We truly appreciate Mr. Davis’ outstanding contributions to MicroPort Orthopedics, especially throughout the organization transition and we are most grateful for his efforts in building solid foundations for the future.
Mr. Sahagun most recently served as Chief Operations Officer ("COO") of MicroPort Orthopedics. He joined MicroPort Orthopedics in January 2014 as Vice President International, following the asset purchase of the OrthoRecon Business from Wright Medical Group, Inc. ("Wright Medical"), and was subsequently promoted to his current position. Mr. Sahagun has also been a member of MicroPort Scientific’s Intercontinental Executive Committee since its inception in early 2014.
During his service with Wright Medical, Mr. Sahagun was the Corporate Officer and the Vice President of Europe, Middle East and Africa ("EMEA") Commercial Operations since 2011, and had previously served as Vice President of Sales for the region since 2010. He joined Wright Medical in early 2006 as Director of Finance and Operations in France, and served as both Director of Finance of EMEA and Vice President of Finance of EMEA prior to the positions above. Before Wright Medical, Mr. Sahagun worked for Medtronic where he provided senior financial support to the company's Spine business across Europe.
Mr. Sahagun began his career in Spain, where he held several finance and business management positions in banking and distribution organizations with increased responsibilities covering Spain, Portugal and Latin-America.
Mr. Sahagun holds an MBA degree from HEC (Paris, France), a Bachelor's degree in Economics from UAM (Autonomous University of Madrid, Spain), and has followed additional Executive Education programs at Stanford Graduate School of Business (Stanford, CA - USA) and Harvard Business School (Cambridge, MA - USA).
Please join us in congratulating Aurelio for his new appointment as the Board of Directors believe his leadership, vision and passion will help MPO to succeed in the going forward and can bring the organization to the next level.
MicroPort Scientific Corporation Announces membership changes in the Greater China Executive Committee(“CEC”)and Intercontinental Executive committee (“IEC”)
Effective September 8th, 2015, the following membership changes will occur for the Greater China Executive Committee and Intercontinental Executive Committee
Greater China Executive Committee:
- Bo Peng, will continue to be the Chairperson for the CEC
- Hongbin Sun, will continue to be the Co-Chairperson for the CEC
- Jason Zhang-recently joined MPSC will be the new member of the CEC.
CEC Members: Bo Peng, Hongbin Sun, Jason Zhang, Qiyi Luo, Karl Pan, Yimin Xu and Junder Chiang
Intercontinental Executive Committee:
- Jonathan Chen, currently Co-Chairperson of the IEC has been appointed as the Chairperson of the IEC
- Aurelio Sahagun, currently an IEC member has been appointed as the Co-Chairperson of the IEC.
- Jason Zhang – recently joined MPSC as COO and will be a new member of the IEC
- Todd Smith, currently Vice President of Finance for MicroPort Orthopedics, will be a new member of the IEC
IEC Members: Jonathan Chen, Aurelio Sahagun, Hongbin Sun, Jason Zhang, Qiyi Luo, Todd Smith, and Junder Chiang

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:MicroPort® Attends the Ninth Oriental Cardiology Meeting
[Next]:MicroPort® Lifesciences Attends the Fourteenth National Endocrinology Conference of Chinese Medical Association